$643.31 Million in Sales Expected for Teleflex Incorporated (NYSE:TFX) This Quarter

Wall Street analysts expect Teleflex Incorporated (NYSE:TFX) to announce sales of $643.31 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Teleflex’s earnings. The lowest sales estimate is $641.30 million and the highest is $648.20 million. Teleflex posted sales of $609.67 million in the same quarter last year, which suggests a positive year-over-year growth rate of 5.5%. The business is scheduled to report its next earnings report on Thursday, November 7th.

According to Zacks, analysts expect that Teleflex will report full year sales of $2.60 billion for the current financial year, with estimates ranging from $2.59 billion to $2.60 billion. For the next year, analysts forecast that the company will report sales of $2.78 billion, with estimates ranging from $2.76 billion to $2.82 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Teleflex.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, August 1st. The medical technology company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.07. Teleflex had a net margin of 10.78% and a return on equity of 18.57%. The business had revenue of $652.50 million for the quarter, compared to analysts’ expectations of $637.06 million. During the same period in the previous year, the company posted $2.47 earnings per share. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year.

A number of research analysts have recently commented on TFX shares. Morgan Stanley boosted their target price on shares of Teleflex from $345.00 to $392.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Barclays upped their price target on shares of Teleflex from $309.00 to $356.00 and gave the company an “equal weight” rating in a report on Monday, August 5th. Raymond James upped their price target on shares of Teleflex from $350.00 to $420.00 and gave the company a “strong-buy” rating in a report on Friday, August 2nd. Zacks Investment Research cut shares of Teleflex from a “buy” rating to a “hold” rating in a report on Tuesday, May 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $403.00 price target (up from $325.00) on shares of Teleflex in a report on Friday, August 2nd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $367.67.

In other news, VP John Deren sold 2,004 shares of the company’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $365.06, for a total transaction of $731,580.24. Following the completion of the transaction, the vice president now owns 3,046 shares in the company, valued at $1,111,972.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $295.81, for a total transaction of $59,162.00. Following the transaction, the director now owns 936 shares of the company’s stock, valued at approximately $276,878.16. The disclosure for this sale can be found here. Insiders have sold 38,453 shares of company stock valued at $12,516,242 in the last 90 days. Insiders own 2.36% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in Teleflex by 4.6% during the fourth quarter. Geode Capital Management LLC now owns 410,714 shares of the medical technology company’s stock valued at $106,085,000 after buying an additional 17,913 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in Teleflex by 52.1% during the first quarter. State of Alaska Department of Revenue now owns 7,584 shares of the medical technology company’s stock valued at $2,289,000 after buying an additional 2,598 shares in the last quarter. Virtu Financial LLC purchased a new stake in Teleflex during the first quarter valued at about $878,000. Pennsylvania Trust Co lifted its stake in Teleflex by 4,183.1% during the first quarter. Pennsylvania Trust Co now owns 114,574 shares of the medical technology company’s stock valued at $4,916,000 after buying an additional 111,899 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new stake in Teleflex during the first quarter valued at about $31,000. Institutional investors and hedge funds own 90.07% of the company’s stock.

Shares of NYSE TFX traded down $1.62 during trading on Thursday, reaching $366.16. 315,600 shares of the stock were exchanged, compared to its average volume of 339,620. The business’s 50-day moving average price is $350.33 and its 200 day moving average price is $311.01. Teleflex has a twelve month low of $226.02 and a twelve month high of $373.90. The company has a quick ratio of 1.59, a current ratio of 2.52 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $17.10 billion, a price-to-earnings ratio of 36.99, a price-to-earnings-growth ratio of 2.45 and a beta of 1.02.

The company also recently declared a quarterly dividend, which will be paid on Monday, September 16th. Stockholders of record on Thursday, August 15th will be given a dividend of $0.34 per share. The ex-dividend date is Wednesday, August 14th. This represents a $1.36 annualized dividend and a dividend yield of 0.37%. Teleflex’s dividend payout ratio is currently 13.74%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

See Also: What is a death cross?

Get a free copy of the Zacks research report on Teleflex (TFX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.